Rostec’s subsidiary Nacimbio has completed the first phase of clinical trials of the rotavirus vaccine. The new drug will be packaged in Russia in 2020 already, while the full production cycle will be launched in 2026.
Rostec’s subsidiary National Immunobiological Company (Nacimbio) localizes production of the rotavirus vaccine in Russia in accordance with the agreement with Indian partners. An exclusive agreement on transfer of vaccine production technologies was signed by Farm Aid Ltd. (established by National Immunobiological Company in cooperation with Ishvan Pharmaceuticals, UAE) and the two largest global biotechnology companies, Serum Institute of India and Zydus Cadila (Healthcare) in 2017.
It is planned that by 2020, the Russian company will package the vaccine. The full production cycle, including production of antigens, will be launched in 2026. The project is a result of integration in the sphere of pharmaceutical manufacturing carried out by the holding company.
“The Russian Ministry of Healthcare aims to add rotavirus vaccines to the National Immunization Calendar in 2020. By this time we will be able to fully meet the needs stated in the government order. The supply of the rotavirus vaccine in the interests of the Ministry of Healthcare may total 4.5 million doses per year,” said Executive Director of Rostec Oleg Yevtushenko.
Nacimbio was established in order to create a holding company (integrated structure) of Rostec in the sphere of development and production of immunobiological products. The holding company is meant to ensure Russia’s independence from imports in the sphere of healthcare and provision of drugs. To achieve this, the holding company comprises Microgen Scientific-cum-Production Association, FORT, and Sintez.
Farm Aid Ltd. was established on May 26, 2017 as a joint venture of Nacimbio representing Rostec’s pharmaceutical holding company, and Ishvan Pharmaceutical Ltd (UAE). Ishvan has a 51% stake in Farm Aid Ltd., while the share of Nacimbio is 49%. The company’s key objectives include transfer of technologies, localization of innovative combined and immunobiological drugs production in Russia, and ensuring easier availability of effective therapy for Russian patients. Due to the project implementation, new Russian drugs which have not been on the market will be available at a reasonable price and will ensure saving of the federal healthcare budget.